Risk Evaluation and Mitigation Strategy (REMS)

IMPORTANT PROGRAM UPDATE:

As of March 8, 2022, the Qsymia Healthcare Provider Training Program has been removed as a requirement of the Qsymia REMS and is no longer available on this website.

During the transition period for the Qsymia REMS, VIVUS will not be enrolling new pharmacies into the program for several months.

Risk Evaluation and Mitigation Strategy (REMS)

A Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage known or potential serious risks associated with a drug product and is required by the Food and Drug Administration (FDA) to ensure that the benefits of a drug outweigh its risks. The FDA has required a REMS for Qsymia.

The purpose of the Qsymia REMS is to inform certified pharmacies and patients of reproductive potential about the:

  • Increased risk of congenital malformation, specifically orofacial clefts, in infants exposed to Qsymia during the first trimester of pregnancy
  • Importance of pregnancy prevention for patients of reproductive potential receiving Qsymia
  • Need to discontinue Qsymia immediately if pregnancy occurs

Dispensed to Patients Through Certified Pharmacies

Qsymia is available only through certified pharmacies. Click Here to learn more.

 

Full Prescribing Information

Materials for Patients

Risk of Birth Defects with Qsymia patient brochure

Medication Guide

These materials can be downloaded and printed.